Key Takeaways BSX's Q3 gross and operating margins improved on a favorable mix from EP and WATCHMAN growth.BSX's WATCHMAN sales jumped 35% with rising U.S. concomitant adoption and broader patient penetration.BSX's EP sales surged 63% as FARAPULSE adoption accelerated, supported by OPAL HDx system uptake.Boston Scientific (BSX) posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior-year period. The increase was mainly driven ...